Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian C Gaertner

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phaseGeorg F Weber, Florian C Gaertner, Wolfgang Erl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
<sup>68</sup>Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boostLena Thomas, Steffi Kantz, Arthur Hung, et al.
Physiological Measurement|January 6, 2017
Matching the reaction-diffusion simulation to dynamic [<sup>18</sup>F]FMISO PET measurements in tumors: extension to a flow-limited oxygen-dependent modelKuangyu Shi, Christine Bayer, Florian C Gaertner, et al.
EJNMMI Research|November 30, 2019
Biodistribution and post-therapy dosimetric analysis of [<sup>177</sup>Lu]Lu-DOTA<sup>ZOL</sup> in patients with osteoblastic metastases: first resultsAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Molecular Imaging and Biology|July 6, 2016
Quantitative Analysis of [<sup>18</sup>F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with ImmunohistochemistryKuangyu Shi, Christine Bayer, Sabrina T Astner, et al.
Investigative Radiology|February 7, 2013
Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumorsFlorian C Gaertner, Ambros J Beer, Michael Souvatzoglou, et al.
Oncotarget|September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichlorideHojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
Oncology Letters|January 21, 2017
<sup>18</sup>F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumorSied Kebir, Okka Kimmich, Pitt Niehusmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2016
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617Justin Ferdinandus, Elisabeth Eppard, Florian C Gaertner, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phaseGeorg F Weber, Florian C Gaertner, Wolfgang Erl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 23, 2018
<sup>68</sup>Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boostLena Thomas, Steffi Kantz, Arthur Hung, et al.
Physiological Measurement|January 6, 2017
Matching the reaction-diffusion simulation to dynamic [<sup>18</sup>F]FMISO PET measurements in tumors: extension to a flow-limited oxygen-dependent modelKuangyu Shi, Christine Bayer, Florian C Gaertner, et al.
EJNMMI Research|November 30, 2019
Biodistribution and post-therapy dosimetric analysis of [<sup>177</sup>Lu]Lu-DOTA<sup>ZOL</sup> in patients with osteoblastic metastases: first resultsAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Molecular Imaging and Biology|July 6, 2016
Quantitative Analysis of [<sup>18</sup>F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with ImmunohistochemistryKuangyu Shi, Christine Bayer, Sabrina T Astner, et al.
Investigative Radiology|February 7, 2013
Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumorsFlorian C Gaertner, Ambros J Beer, Michael Souvatzoglou, et al.
Oncotarget|September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichlorideHojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
Oncology Letters|January 21, 2017
<sup>18</sup>F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumorSied Kebir, Okka Kimmich, Pitt Niehusmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2016
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617Justin Ferdinandus, Elisabeth Eppard, Florian C Gaertner, et al.
Pageof 6